News

The ReNeuron Group Plc has entered into an exclusive licensing agreement with a subsidiary of the Shanghai Fosun Pharmaceutical (Group) Co Ltd of China for the development, manufacture and commercialisation of its two allogeneic cell lines which underpin the UK company’s candidate cell therapies for neurological disorders and diseases of the retina.

Germany’s Medigene AG has secured a licensing and collaboration deal with a new Asian biotech which will develop and commercialise its prospective T cell immunotherapies in China, South Korea and Japan. The new company, Cytovant Sciences, has been launched by Roivant Sciences Ltd of Switzerland and Sinovant Sciences in China.

The Dutch biotech, Synaffix BV has secured a deal in China that expands the use of its conjugation technology for antibody-drug conjugates (ADC), while generating income of up to $125 million. Announced on 10 April, the agreement will give Shanghai Miracogen Inc non-exclusive rights to two of Synaffix’s proprietary technologies. One is a conjugation technology that exploits the native glycan for the attachment of a toxic payload to an antibody; the other uses polar spacer technology to link the antibody to a cargo.

With public health authorities increasingly vigilant about another influenza pandemic, the European Commission and 15 EU member states have signed contracts with Seqirus UK Ltd for the supply of influenza vaccines that might be used in an emergency. Announcing the deal on 8 April, the company said the pandemic contracts are the first to be executed under a new EU joint procurement framework. Financial terms were not disclosed.

The UK gene therapy company Autolus Therapeutics Plc has raised $100.8 million in a US public share offering to support its portfolio of programmed T cell therapies for the treatment of cancer. This follows the issue of 4.2 million American Depositary Shares (ADSs) representing 4.2 million ordinary shares which were priced at $24 per ADS. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 630,000 ADSs at the public offering price.

An early stage chimeric antigen receptor (CAR) T cell therapy that targets an antigen expressed on myeloma cells has been singled out for a fast-track review by the European Medicines Agency. The cell-based gene therapy, JNJ-4528, is being co-developed by Nanjing Legend Biotech Co of China and Janssen Research & Development LLC.

AveXis, a gene therapy company acquired by Novartis in 2018, is to expand its manufacturing capacity with the purchase of an advanced biologics facility in Colorado, US. This coincides with the US regulatory review of the company’s gene therapy for spinal muscular atrophy (SMA), a neuromuscular disease.

The Food and Drug Administration is expected to deliver a decision on marketing authorisation in May. AveXis will also seek regulatory approvals for the therapy in the EU and Japan.

Cambridge Innovation Capital Plc, a venture capital company supporting businesses in and around Cambridge, UK has raised £150 million in new capital to support its portfolio of healthcare and technology companies. The financing is one of the largest private rounds in Europe this year and more than doubles to £275 million the resources available to the company.

Novartis is to spend $310 million upfront to acquire a portfolio of candidate small molecule drugs targeting a pathway in the innate immune system that could potentially treat chronic inflammatory disorders as well as nonalcoholic steatohepatitis (NASH), a condition in which fat builds up in the liver.

Evotec AG continued to benefit in 2018 from its dual business model as a service provider and drug discoverer and developer, delivering a 42% increase in revenue to €375 million and a near doubling of operating profit to €77.5 million. One feature of the year was the full integration of the Aptuit contract research organisation, acquired in 2017. Another was a new alliance with Celgene Corp in targeted protein degradation.